BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 12702581)

  • 1. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor.
    Vu TH; Chuyen NV; Li T; Hoffman AR
    Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
    Yun K; Fidler AE; Eccles MR; Reeve AE
    Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor.
    Xu YQ; Grundy P; Polychronakos C
    Oncogene; 1997 Mar; 14(9):1041-6. PubMed ID: 9070652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.
    Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP
    Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor.
    Vu TH; Hoffman A
    J Biol Chem; 1996 Apr; 271(15):9014-23. PubMed ID: 8621549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting.
    Li X; Adam G; Cui H; Sandstedt B; Ohlsson R; Ekström TJ
    Oncogene; 1995 Jul; 11(2):221-9. PubMed ID: 7624139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mosaic allelic insulin-like growth factor 2 expression patterns reveal a link between Wilms' tumorigenesis and epigenetic heterogeneity.
    Ohlsson R; Cui H; He L; Pfeifer S; Malmikumpu H; Jiang S; Feinberg AP; Hedborg F
    Cancer Res; 1999 Aug; 59(16):3889-92. PubMed ID: 10463576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered specificity of IGF2 promoter imprinting during fetal development and onset of Wilms tumour.
    Taniguchi T; Schofield AE; Scarlett JL; Morison IM; Sullivan MJ; Reeve AE
    Oncogene; 1995 Aug; 11(4):751-6. PubMed ID: 7651739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma.
    Nonomura N; Nishimura K; Miki T; Kanno N; Kojima Y; Yokoyama M; Okuyama A
    Cancer Res; 1997 Jul; 57(13):2575-7. PubMed ID: 9205056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation.
    Sullivan MJ; Taniguchi T; Jhee A; Kerr N; Reeve AE
    Oncogene; 1999 Dec; 18(52):7527-34. PubMed ID: 10602511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
    Wang WH; Duan JX; Vu TH; Hoffman AR
    J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.
    Ogawa O; Eccles MR; Szeto J; McNoe LA; Yun K; Maw MA; Smith PJ; Reeve AE
    Nature; 1993 Apr; 362(6422):749-51. PubMed ID: 8097018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative reverse transcription-polymerase chain reaction and in situ hybridization analyses of human imprinted p57KIP2 and insulin-like growth factor 2 gene transcripts in fetal kidney and Wilms' tumors using archival tissue.
    Soejima H; McLay J; Hatada I; Mukai T; Jinno Y; Niikawa N; Yun K
    Lab Invest; 1998 Jan; 78(1):19-28. PubMed ID: 9461119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism.
    Ogawa O; Becroft DM; Morison IM; Eccles MR; Skeen JE; Mauger DC; Reeve AE
    Nat Genet; 1993 Dec; 5(4):408-12. PubMed ID: 8298652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of imprinting of IGF2 in Ewing's sarcoma.
    Zhan S; Shapiro DN; Helman LJ
    Oncogene; 1995 Dec; 11(12):2503-7. PubMed ID: 8545106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of imprinting in hepatoblastoma.
    Rainier S; Dobry CJ; Feinberg AP
    Cancer Res; 1995 May; 55(9):1836-8. PubMed ID: 7728748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis.
    Cui H; Hedborg F; He L; Nordenskjöld A; Sandstedt B; Pfeifer-Ohlsson S; Ohlsson R
    Cancer Res; 1997 Oct; 57(20):4469-73. PubMed ID: 9377554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter-specific imprinting of the human insulin-like growth factor-II gene.
    Vu TH; Hoffman AR
    Nature; 1994 Oct; 371(6499):714-7. PubMed ID: 7935819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.